112 related articles for article (PubMed ID: 9482117)
1. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of DNA binding and transcriptional regulatory function of an endogenous mutant p53 in MDA-468 human breast cancer cells.
Prasad KA; Church JG
Biochem Biophys Res Commun; 1997 Mar; 232(1):14-9. PubMed ID: 9125118
[TBL] [Abstract][Full Text] [Related]
3. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
4. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
5. Inactive p53 mutants may enhance the transcriptional activity of wild-type p53.
Zhang W; Shay JW; Deisseroth A
Cancer Res; 1993 Oct; 53(20):4772-5. PubMed ID: 8402659
[TBL] [Abstract][Full Text] [Related]
6. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
8. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
Chen JY; Funk WD; Wright WE; Shay JW; Minna JD
Oncogene; 1993 Aug; 8(8):2159-66. PubMed ID: 8336941
[TBL] [Abstract][Full Text] [Related]
10. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53.
Kichina JV; Rauth S; Das Gupta TK; Gudkov AV
Oncogene; 2003 Jul; 22(31):4911-7. PubMed ID: 12894234
[TBL] [Abstract][Full Text] [Related]
11. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
[TBL] [Abstract][Full Text] [Related]
12. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.
Abarzúa P; LoSardo JE; Gubler ML; Neri A
Cancer Res; 1995 Aug; 55(16):3490-4. PubMed ID: 7627952
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional regulation and induction of apoptosis: implications for the use of monomeric p53 variants in gene therapy.
Merkle C; Fritsche M; Mundt M; Jähne R; Groner B
Gene Ther; 1998 Dec; 5(12):1631-41. PubMed ID: 10023442
[TBL] [Abstract][Full Text] [Related]
14. Targeting gene expression to tumor cells with loss of wild-type p53 function.
Zhu J; Gao B; Zhao J; Balmain A
Cancer Gene Ther; 2000 Jan; 7(1):4-12. PubMed ID: 10678350
[TBL] [Abstract][Full Text] [Related]
15. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast.
Flaman JM; Robert V; Lenglet S; Moreau V; Iggo R; Frebourg T
Oncogene; 1998 Mar; 16(10):1369-72. PubMed ID: 9546439
[TBL] [Abstract][Full Text] [Related]
16. Response of Ewing tumor cells to forced and activated p53 expression.
Kovar H; Pospisilova S; Jug G; Printz D; Gadner H
Oncogene; 2003 May; 22(21):3193-204. PubMed ID: 12761489
[TBL] [Abstract][Full Text] [Related]
17. Novel DNA binding of p53 mutants and their role in transcriptional activation.
Zhang W; Funk WD; Wright WE; Shay JW; Deisseroth AB
Oncogene; 1993 Sep; 8(9):2555-9. PubMed ID: 8361764
[TBL] [Abstract][Full Text] [Related]
18. The region 3' to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins.
Strauss BE; Haas M
Biochem Biophys Res Commun; 1995 Dec; 217(1):333-40. PubMed ID: 8526930
[TBL] [Abstract][Full Text] [Related]
19. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
[TBL] [Abstract][Full Text] [Related]
20. Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization.
Jõers A; Kristjuhan A; Kadaja L; Maimets T
Oncogene; 1998 Nov; 17(18):2351-8. PubMed ID: 9811466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]